AU2009259451B2 - 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases - Google Patents
5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases Download PDFInfo
- Publication number
- AU2009259451B2 AU2009259451B2 AU2009259451A AU2009259451A AU2009259451B2 AU 2009259451 B2 AU2009259451 B2 AU 2009259451B2 AU 2009259451 A AU2009259451 A AU 2009259451A AU 2009259451 A AU2009259451 A AU 2009259451A AU 2009259451 B2 AU2009259451 B2 AU 2009259451B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- substituted
- unsubstituted
- tnf
- alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/139,661 US7781594B2 (en) | 2008-06-16 | 2008-06-16 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
| US12/139,661 | 2008-06-16 | ||
| EP08380177.9 | 2008-06-16 | ||
| EP08380177A EP2135864A1 (en) | 2008-06-16 | 2008-06-16 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
| PCT/EP2009/057324 WO2009153226A1 (en) | 2008-06-16 | 2009-06-15 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2009259451A1 AU2009259451A1 (en) | 2009-12-23 |
| AU2009259451B2 true AU2009259451B2 (en) | 2013-03-14 |
Family
ID=43414178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009259451A Ceased AU2009259451B2 (en) | 2008-06-16 | 2009-06-15 | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP2313382A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011524352A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20110022679A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102083806A (cg-RX-API-DMAC7.html) |
| AR (1) | AR072113A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009259451B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0915325A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2728139A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO6331429A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL209801A0 (cg-RX-API-DMAC7.html) |
| MA (1) | MA32473B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010013978A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ589894A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2495031C2 (cg-RX-API-DMAC7.html) |
| SA (1) | SA109300384B1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI403506B (cg-RX-API-DMAC7.html) |
| UY (1) | UY31896A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009153226A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201008877B (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| RU2502513C2 (ru) * | 2012-01-11 | 2013-12-27 | Государственное бюджетное учреждение здравоохранения Свердловской области "Свердловский областной клинический психоневрологический госпиталь для ветеранов войн" (ГБУЗ СО "СОКП Госпиталь для ветеранов войн") | Способ лечения больных с полиорганной патологией озонотерапией |
| UA127354C2 (uk) * | 2017-11-23 | 2023-07-26 | Іммунік Аґ | Спосіб профілактики або лікування хронічних запальних і/або аутоімунних захворювань відофлудимусом |
| KR102076936B1 (ko) * | 2019-08-12 | 2020-02-13 | 연세대학교 산학협력단 | 티아졸 또는 이의 염을 유효성분으로 포함하는 알러지성 질환 또는 아토피 피부염 예방 또는 치료용 조성물 |
| IT202000008125A1 (it) * | 2020-04-16 | 2021-10-16 | Minerva Srl | Acidi carbossilici 3-aza-biciclo[3.2.1]ottani e loro derivati per l’uso nel trattamento di infiammazioni |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026902A1 (en) * | 2003-01-31 | 2005-02-03 | Timothy Maziasz | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990009381A1 (en) * | 1989-02-08 | 1990-08-23 | Abbott Laboratories | 4-hydroxythiazoles as 5-lipoxygenase inhibitors |
| JPH10504542A (ja) * | 1994-07-27 | 1998-05-06 | ジー.ディー.サール アンド カンパニー | 炎症処置用の置換チアゾール化合物 |
| ATE301457T1 (de) * | 1995-06-12 | 2005-08-15 | Searle & Co | Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor |
| AU7559200A (en) * | 1999-10-12 | 2001-04-23 | Japan Tobacco Inc. | Hypertriglyceridemia remedies and antiobestics |
| HRP20040098B1 (en) * | 2001-08-13 | 2012-08-31 | Janssen Pharmaceutica N.V. | 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY |
-
2009
- 2009-06-06 TW TW098118927A patent/TWI403506B/zh not_active IP Right Cessation
- 2009-06-12 AR ARP090102121A patent/AR072113A1/es unknown
- 2009-06-12 UY UY0001031896A patent/UY31896A/es not_active Application Discontinuation
- 2009-06-15 AU AU2009259451A patent/AU2009259451B2/en not_active Ceased
- 2009-06-15 BR BRPI0915325A patent/BRPI0915325A2/pt not_active IP Right Cessation
- 2009-06-15 SA SA109300384A patent/SA109300384B1/ar unknown
- 2009-06-15 EP EP09765806A patent/EP2313382A1/en not_active Withdrawn
- 2009-06-15 MX MX2010013978A patent/MX2010013978A/es active IP Right Grant
- 2009-06-15 KR KR1020117001228A patent/KR20110022679A/ko not_active Ceased
- 2009-06-15 NZ NZ589894A patent/NZ589894A/en not_active IP Right Cessation
- 2009-06-15 CN CN2009801226820A patent/CN102083806A/zh active Pending
- 2009-06-15 WO PCT/EP2009/057324 patent/WO2009153226A1/en not_active Ceased
- 2009-06-15 JP JP2011513001A patent/JP2011524352A/ja active Pending
- 2009-06-15 CA CA2728139A patent/CA2728139A1/en not_active Abandoned
- 2009-06-15 RU RU2011101439/04A patent/RU2495031C2/ru not_active IP Right Cessation
-
2010
- 2010-12-06 IL IL209801A patent/IL209801A0/en unknown
- 2010-12-09 ZA ZA2010/08877A patent/ZA201008877B/en unknown
-
2011
- 2011-01-13 MA MA33516A patent/MA32473B1/fr unknown
- 2011-01-14 CO CO11003796A patent/CO6331429A2/es active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050026902A1 (en) * | 2003-01-31 | 2005-02-03 | Timothy Maziasz | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI403506B (zh) | 2013-08-01 |
| RU2011101439A (ru) | 2012-07-27 |
| ZA201008877B (en) | 2012-02-29 |
| IL209801A0 (en) | 2011-02-28 |
| TW201010988A (en) | 2010-03-16 |
| CO6331429A2 (es) | 2011-10-20 |
| AR072113A1 (es) | 2010-08-04 |
| KR20110022679A (ko) | 2011-03-07 |
| RU2495031C2 (ru) | 2013-10-10 |
| NZ589894A (en) | 2011-08-26 |
| AU2009259451A1 (en) | 2009-12-23 |
| WO2009153226A1 (en) | 2009-12-23 |
| JP2011524352A (ja) | 2011-09-01 |
| CN102083806A (zh) | 2011-06-01 |
| EP2313382A1 (en) | 2011-04-27 |
| CA2728139A1 (en) | 2009-12-23 |
| SA109300384B1 (ar) | 2013-04-20 |
| UY31896A (es) | 2010-01-29 |
| BRPI0915325A2 (pt) | 2015-10-27 |
| MX2010013978A (es) | 2011-03-29 |
| MA32473B1 (fr) | 2011-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110088105B (zh) | Jak家族激酶的小分子抑制剂 | |
| EP3243821B1 (en) | Pharmaceutical formulations for regulating integrin cd11b/cd18 | |
| JP6499165B2 (ja) | 二重選択的pi3デルタ及びガンマキナーゼ阻害剤 | |
| TW201808945A (zh) | 磷脂酸肌醇3-激酶γ的新穎抑制劑 | |
| AU2009259451A1 (en) | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases | |
| BR112017010471B1 (pt) | Compostos de di-hidropirimidin-2-ona, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| US11160801B2 (en) | RORgamma modulators and uses thereof | |
| JP2019528300A (ja) | インドールアミン2,3−ジオキシゲナーゼの阻害剤およびその使用方法 | |
| EP4273143B1 (en) | Derivative of 2,5-diketopiperazine compound, and preparation method therefor, pharmaceutical composition thereof and use thereof | |
| US8492411B2 (en) | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases | |
| CN108558810B (zh) | 具有rock激酶抑制作用的黄酮类衍生物 | |
| EP2135864A1 (en) | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases | |
| CA2618970C (en) | Lisofylline analogs and methods for use | |
| JP2004509167A (ja) | 安息香酸誘導体及びその使用方法 | |
| HK1157325A (en) | 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases | |
| JP3623228B1 (ja) | テトラヒドロ−2h−チオピラン−4−カルボキサミド誘導体 | |
| JP2006241144A (ja) | テトラヒドロ−2h−チオピラン−4−カルボキサミド誘導体を含有する医薬組成物 | |
| TW202317093A (zh) | 具有hiv複製抑制作用之縮合雜環衍生物 | |
| CN112409349A (zh) | 激酶抑制剂及其制备、药物组合物和用途 | |
| TW202225167A (zh) | 一種嘧啶甲醯胺類化合物及其應用 | |
| CN113727713A (zh) | 氟取代的2-氨基噻唑-5-芳香族甲酰胺的用途 | |
| JP2001316262A (ja) | 抗酸化剤 | |
| JP2000095690A (ja) | 血管新生阻害剤 | |
| JP2022527641A (ja) | Cxcr4モジュレーターとしてのイミダゾリン誘導体 | |
| HK1142542A (en) | Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |